BIOTE CORP -A (BTMD)
US0906831039 - Common Stock
Taking everything into account, BTMD scores 6 out of 10 in our fundamental rating. BTMD was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BTMD get a neutral evaluation. Nothing too spectacular is happening here. An interesting combination arises when we look at growth and value: BTMD is growing strongly while it also seems undervalued. These ratings could make BTMD a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
BTMD had a positive operating cash flow in the past year.
Of the past 5 years BTMD 4 years were profitable.
BTMD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BTMD has a Return On Assets of 5.03%. This is amongst the best in the industry. BTMD outperforms 88.08% of its industry peers.
BTMD has a better Return On Invested Capital (17.54%) than 94.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.03% | ||
| ROE | N/A | ||
| ROIC | 17.54% |
ROA(3y)20.43%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of BTMD (4.30%) is better than 86.01% of its industry peers.
In the last couple of years the Profit Margin of BTMD has declined.
BTMD has a better Operating Margin (16.66%) than 86.53% of its industry peers.
In the last couple of years the Operating Margin of BTMD has declined.
The Gross Margin of BTMD (69.37%) is better than 72.54% of its industry peers.
BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.66% | ||
| PM (TTM) | 4.3% | ||
| GM | 69.37% |
OM growth 3Y-17.24%
OM growth 5YN/A
PM growth 3Y-58.51%
PM growth 5YN/A
GM growth 3Y3.85%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
The number of shares outstanding for BTMD has been increased compared to 1 year ago.
BTMD has a better debt/assets ratio than last year.
2.2 Solvency
BTMD has an Altman-Z score of 3.64. This indicates that BTMD is financially healthy and has little risk of bankruptcy at the moment.
BTMD's Altman-Z score of 3.64 is fine compared to the rest of the industry. BTMD outperforms 79.27% of its industry peers.
BTMD has a debt to FCF ratio of 6.24. This is a slightly negative value and a sign of low solvency as BTMD would need 6.24 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 6.24, BTMD belongs to the best of the industry, outperforming 83.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 6.24 | ||
| Altman-Z | 3.64 |
ROIC/WACC1.97
WACC8.91%
2.3 Liquidity
BTMD has a Current Ratio of 4.75. This indicates that BTMD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.75, BTMD perfoms like the industry average, outperforming 58.55% of the companies in the same industry.
A Quick Ratio of 3.97 indicates that BTMD has no problem at all paying its short term obligations.
BTMD has a Quick ratio (3.97) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.75 | ||
| Quick Ratio | 3.97 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 114.47%, which is quite impressive.
BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -66.72% yearly.
The Revenue has grown by 8.49% in the past year. This is quite good.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.71% yearly.
EPS 1Y (TTM)114.47%
EPS 3Y-66.72%
EPS 5YN/A
EPS Q2Q%84.62%
Revenue 1Y (TTM)8.49%
Revenue growth 3Y16.71%
Revenue growth 5YN/A
Sales Q2Q%4.37%
3.2 Future
BTMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.22% yearly.
Based on estimates for the next years, BTMD will show a quite strong growth in Revenue. The Revenue will grow by 16.62% on average per year.
EPS Next Y222.09%
EPS Next 2Y118.67%
EPS Next 3Y75.78%
EPS Next 5Y87.22%
Revenue Next Year8.94%
Revenue Next 2Y12.39%
Revenue Next 3Y14.42%
Revenue Next 5Y16.62%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 67.27, the valuation of BTMD can be described as expensive.
Based on the Price/Earnings ratio, BTMD is valued a bit cheaper than the industry average as 79.27% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.16, BTMD is valued quite expensively.
A Price/Forward Earnings ratio of 12.09 indicates a correct valuation of BTMD.
85.49% of the companies in the same industry are more expensive than BTMD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 20.02. BTMD is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 67.27 | ||
| Fwd PE | 12.09 |
4.2 Price Multiples
BTMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BTMD is cheaper than 80.83% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 81.87% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.68 | ||
| EV/EBITDA | 14.42 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
BTMD's earnings are expected to grow with 75.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y118.67%
EPS Next 3Y75.78%
5. Dividend
5.1 Amount
BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOTE CORP -A
NASDAQ:BTMD (7/1/2024, 7:23:04 PM)
After market: 7.4 0 (0%)7.4
-0.07 (-0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap459.10M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 67.27 | ||
| Fwd PE | 12.09 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.3
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.03% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 16.66% | ||
| PM (TTM) | 4.3% | ||
| GM | 69.37% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.75 | ||
| Quick Ratio | 3.97 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)114.47%
EPS 3Y-66.72%
EPS 5Y
EPS Q2Q%
EPS Next Y222.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.49%
Revenue growth 3Y16.71%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y